Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
For years, medtech firms around the globe (and certainly European companies) introduced their products in Europe, which requires obtaining a CE ...
BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...
ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...
Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies ...
MD and Partner at BCG's healthcare practice. Industry insiders pushed for more business-friendly policies in the world's fifth-largest economy, which is heavily dependent on China for drug-related raw ...
India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw material imports at a time when many global pharmaceutical firms are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback